z-logo
open-access-imgOpen Access
Sperm-Associated Antigen 16 Is a Novel Target of the Humoral Autoimmune Response in Multiple Sclerosis
Author(s) -
Laura Bock,
Klaartje Somers,
Judith Fraussen,
Jerome J. A. Hendriks,
Jack van Horssen,
Myrthe Rouwette,
Niels Hellings,
Luisa María Villar,
José C. ÁlvarezCermeño,
Mercedes Espiño,
Raymond Hupperts,
Peter Joseph Jongen,
Jan Damoiseaux,
Marcel M. Verbeek,
Peter Paul De Deyn,
Marie D’hooghe,
Bart Van Wijmeersch,
Piet Stinissen,
Veerle Somers
Publication year - 2014
Publication title -
the journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.737
H-Index - 372
eISSN - 1550-6606
pISSN - 0022-1767
DOI - 10.4049/jimmunol.1401166
Subject(s) - autoantibody , multiple sclerosis , cerebrospinal fluid , medicine , experimental autoimmune encephalomyelitis , immunology , antigen , autoimmune disease , biomarker , encephalomyelitis , clinical significance , pathology , antibody , biology , biochemistry
We have previously identified eight novel autoantibody targets in the cerebrospinal fluid of multiple sclerosis (MS) patients, including sperm-associated Ag 16 (SPAG16). In the current study, we further investigated the autoantibody response against SPAG16-a protein with unknown function in the CNS-and its expression in MS pathology. Using isoelectric focusing, we detected SPAG16-specific oligoclonal bands in the cerebrospinal fluid of 5 of 23 MS patients (22%). Analysis of the anti-SPAG16 Ab reactivity in the plasma of a total of 531 donors using ELISA demonstrated significantly elevated anti-SPAG16 Ab levels (p = 0.002) in 32 of 153 MS patients (21%) compared with all other control groups with 95% specificity for the disease. To investigate the pathologic relevance of anti-SPAG16 Abs in vivo, anti-SPAG16 Abs were injected in mice with experimental autoimmune encephalomyelitis, resulting in a significant disease exacerbation. Finally, we demonstrated a consistent upregulation of SPAG16 in MS brain and experimental autoimmune encephalomyelitis spinal cord lesions, more specifically in reactive astrocytes. We conclude that SPAG16 is a novel autoantibody target in a subgroup of MS patients and in combination with other diagnostic criteria, elevated levels of anti-SPAG16 Abs could be used as a biomarker for diagnosis. Furthermore, the pathologic relevance of anti-SPAG16 Abs was shown in vivo.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom